FGF23 and type 2 diabetes mellitus: In fact, we reported previously that Fibroblast Growth Factor (FGF-23), a phosphaturic hormone, predicts adverse cardiovascular outcome in patients with stable coronary artery disease (CAD) and T2DM, but not in patients without T2DM [8].